

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number  
**WO 2005/076975 A2**

(51) International Patent Classification: **Not classified**

(21) International Application Number:  
PCT/US2005/003754

(22) International Filing Date: 4 February 2005 (04.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/542,371 6 February 2004 (06.02.2004) US

(71) Applicant (for all designated States except US): **MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH** [US/US]; 200 First Street S. W., Rochester, MN 55905 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WETTSTEIN, Peter, J.** [US/US]; 508 8th Avenue SW, Rochester, MN



55902 (US). **STRAUSBAUCH, Mike** [US/US]; 4404 8th Street N.W., Rochester, MN 55901 (US). **HARDIN, Heather** [US/US]; 724 18th Avenue NE, Rochester, MN 55906 (US). **BORSON, Nancy** [US/US]; 415 15th Avenue NE, Rochester, MN 55906 (US).

(74) Agent: **ELLINGER, Mark, S.**; Fish & Richardson P.C., P.A., 60 South Sixth Street, Suite 3300, Minneapolis, MN 55402-1104 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: COMPLEXED POLYPEPTIDE AND ADJUVANT FOR IMPROVED VACCINES



(57) Abstract: Attachment of the strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. Accordingly, compositions that include a bipartite immunogenic polypeptide are provided herein. The bipartite polypeptide can include a CpG-interacting amino acid sequence fused to a CTL-activating amino acid sequence that can be heterologous to the CpG-interacting amino acid sequence. Also provided are methods of identifying and using a CpG-interacting amino acid sequence and a bipartite immunogenic polypeptide.

WO 2005/076975 A2



(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*